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Risk of bleeding with non-vitamin K
antagonist oral anticoagulants
Bleeding is the main adverse effect when using oral anticoagulants
(OACs). The risk of major bleeding with vitamin K antagonists
(VKAs) is dependent on the quality of anticoagulation control and
estimated to be 1.3/100 patients/year in patients with INR 2.0–
3.0.1,2 Multiple limitations of VKAs stimulated the development of
non-vitamin K antagonist oral anticoagulants (NOACs) acting dir-
ectly on coagulation factors, including factor FIIa (thrombin) and
FXa. Pharmacological properties of the NOACs relevant for bleed-
ing are summarized in the supplement including Supplementary ma-
terial online, Table S1 and their main effects are summarized in
Supplementary material online, Table S2. The risk of bleeding in
patients managed with NOACs was properly assessed in the
four landmark Phase III trials in patients with atrial fibrillation (AF;
Table 1). Major bleeding was the principal safety outcome in
RE-LY,3,4 ARISTOTLE,5 and ENGAGE AF.6 In ROCKET-AF, the pri-
mary safety endpoint was the composite of major and non-major
clinically relevant bleeding.7 The risk of major bleeding was signifi-
cantly reduced with dabigatran 110 mg b.i.d., apixaban and both
doses of edoxaban3 – 6 while the bleeding rates for dabigatran
150 mg b.i.d. and rivaroxaban were similar to those with warfarin
(Table 1).
Gastrointestinal (GI) bleeding accounts for 90% of major
extracranial haemorrhages in patients with AF receiving VKAs.8
With the NOACs, dabigatran 150 mg b.i.d., rivaroxaban, and edox-
aban 60 mg o.d. significantly increased rates of GI bleeding
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(1.5-fold) compared with warfarin.3,6,7 While rivaroxaban in-
creases upper and lower GI bleeding to a similar extent, dabigatran
150 mg b.i.d. prominently increased lower GI bleeding.9 Apixaban
was associated with GI bleeding rates comparable with those with
warfarin.5 Edoxaban 30 mg o.d. demonstrated significantly lower
rates of GI bleeding compared with warfarin (Table 1).6
Intracranial haemorrhage (ICH) is the major concern in patients
on OACs and this is the field where NOACs demonstrated major
clinical improvement (Table 1). In the four trials, the hazard ratio
for ICH was between 0.31 and 0.64, with meta-analysis showing a
hazard ratio of 0.48 overall.10 Furthermore, the sequelae of ICH
may be less severe when it has occurred during NOAC treatment.11
Major bleeding and ICH rates in ‘real-world’ post-marketing data for
NOACs also seems to be generally reassuring, although GI bleeding
rates appear to be higher for dabigatran (150 mg b.i.d.) compared
with warfarin.12–14
While this paper focuses on the reversal of the effects of NOACs
due to an emergency situation, prevention of bleeding remains of ut-
most importance. The risk of bleeding may be estimated using the
well-validated HAS-BLED score.15 A high HAS-BLED score is there
to ‘flag up’ patients at higher risk of bleeding for more careful review
and follow-up, as well as attention to the potentially reversible risk
factors for bleeding, such as uncontrolled hypertension (systolic
blood pressure.160 mmHg), labile INRs (for VKA user), concomi-
tant use of aspirin/NSAIDs, alcohol excess. Among AF patients, the
HAS-BLED score has been validated to be predictive of bleeding
with VKAs, aspirin, and NOACs.16– 19
The need to reverse the effect of NOACs occurs in case of life-
threatening bleeding, bleeding which cannot be controlled by with-
drawal of OAC and usual care, or medical emergencies other than
bleeding requiring immediate surgery (Figure 1). Intracranial haem-
orrhage, with the highest likelihood for fatal outcome, is one of
the primary aims for reversal agents. A timely administration of re-
versal agents is likely to be of major relevance for an improved clin-
ical outcome in case of ICH. However, bleeding at other sites may
also be life-threatening and risk stratification is more difficult but es-
sential for these bleeding events. A subanalysis of the RE-LY trial
showed that attempts to reverse the effect of dabigatran with clot-
ting factor concentrates (CFCs) were observed in ,2% of all major
bleeding events.20 Despite the lack of a specific reversal agent,
patients in the NOAC arm showed a trend for reduced mortality
associated with major bleeding compared with VKA, most likely
due to a shorter half-life and a lower rate of ICH.20,21 At the present
time, available guidance for reversal of uncontrolled bleeding in pa-
tients treated with NOACs is based on expert opinion rather than
on clinical trials.22– 25
Existing reversal strategies for
non-vitamin K antagonist oral
anticoagulants
As there are no specific antidotes available so far, several therapeutic
interventions have been used, including activated charcoal, haemo-
dialysis, activated charcoal haemoperfusion, fresh frozen plasma
(FFP), and pro-haemostatic agents.22 – 25 This section will focus on
the potential of the pro-haemostatic CFCs for reversal of NOAC
effects encompassing pro-thrombin complex concentrates (PCCs)
and recombinant (r)FVIIa (Novosevenw, NiaStase&). The ESC
Guidelines for the management of AF have recommended consider-
ing these CFCs in case of very severe bleeding.26 Pro-thrombin
complex concentrates, developed for reversal of VKAs, are lyophi-
lized concentrates of vitamin K-dependent coagulation factors avail-
able as: (i) non-activated three-factor PCCs (Profilninew SD,
Bebulinw VH) containing similar amounts of factors II, IX, and X,
and low factor VII levels; (ii) non-activated four-factor PCCs (Beri-
plexw P/N, Kanokadw, Octaplexw, Kaskadilw, Cofactw), containing
adequate levels of factors II, VII, IX, and X, with varying amounts
of heparin and proteins C and S to reduce thrombogenicity; and
(iii) activated four-factor PCC (FEIBAw) containing factors II, IX,
X, and protein C, mainly in non-activated forms, and factor VII main-
ly in the activated form. rFVIIa is a potent general haemostatic
agent.27,28 Fresh frozen plasmas containing normal levels of all
coagulation factors have practical constraints for the rapid reversal
of OACs. A limitation for the use of PCCs is an absolute increase
of thromboembolic events of .1%.29,30 The increase of throm-
boembolic events associated with the use of rFVIIa may be
even higher.31,32
As the effect of pro-haemostatic agents on NOACs has not been
tested in clinical trials so far, our evidence is based on surrogate
endpoints. In comparison, the effect of PCCs on the reversal of
VKA effects has been evaluated in patients with major bleeding or
requiring urgent surgery. However, this evidence is likewise based
on the effect on coagulation tests in small, mostly uncontrolled,
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Table 1 Risk of bleeding with non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation (rates per
100 patients-years)
Dabigatran
110 mg b.i.d.3,4
Dabigatran
150 mg b.i.d.3,4
Rivaroxaban
20 mg o.d.7
Apixaban
5 mg b.i.d.5
Edoxaban
30 mg o.d.6
Edoxaban
60 mg o.d.6
Major bleeding 2.87 vs. 3.57 3.32 vs. 3.57 3.60 vs. 3.40 2.13 vs. 3.09 1.61 vs. 3.43 2.75 vs. 3.43
Major plus NMCR NA NA 20.7 vs. 20.3 4.07 vs. 6.01 7.97 vs. 3.02 11.10 vs. 3.02
ICH 0.23 vs. 0.74 0.30 vs. 0.74 0.50 vs. 0.70 0.33 vs. 0.80 0.26 vs. 0.85 0.39 vs. 0.85
Major GI bleeding 1.12 vs. 1.02 1.51 vs. 1.02 3.20 vs. 2.20 0.76 vs. 0.86 0.82 vs. 1.23 1.51 vs. 1.23
These data derive from separate studies comparing each NOAC to VKA; there are no head-to-head studies between NOACs.
b.i.d., twice daily; o.d., once daily; GI, gastrointestinal; ICH, intracranial haemorrhage; NA, not applicable; NMCR, non-major clinically relevant.
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Figure 1 Practical management of the reversal of non-vitamin K antagonist oral anticoagulants. *: requiring normal haemostasis (for other con-
ditions than bleeding); **: when approved by respective regulatory authorities; idarucizumab has been approved for reversal of the effect of da-
bigatran by the European Medicines Agency and the U.S. Food and Drug Administration; ***: antagonization of concomitant anti-platelet therapy:
† Reconsider combination therapy and hold off anti-platelet therapy until safe/appropriate to restart. † Consider platelet transfusion if receiving
irreversible anti-platelet drug (aspirin, clopidogrel, and prasugrel) or thrombocytopenia. † Consider specific antidote (MEDI2452) if receiving
ticagrelor and when antidote approved by respective regulatory authorities and available.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 New reversal agents for non-vitamin K antagonist oral anticoagulants
Idarucizumab Andexanet Ciraparantag (PER977)
Target Dabigatran Oral direct factor Xa-inhibitors,
low-molecular-weight heparins
and fondaparinux
Oral direct factor Xa and IIa inhibitors,
low-molecular-weight heparins,
un-fractionated heparin and fondaparinux
Structure Humanized Fab fragment Human rFXa variant Synthetic small molecule
Immediate onset of
reversal (,10 min)
Yes Yes Yes
Duration of effect (12 to) 24 h 2 h 24 h
Re-administration
possible
Yes, after 24 h Unknown Currently tested (NCT02207257)
Tested in healthy
volunteers
Yes (NCT020287809) Yes Yes (NCT01826266, NCT02207257)
Elderly Yes Yes (NCT022207725) No
Renally impaired Yes No No
Tested in patients Successful reversal of the specific
effect of dabigatran
(NCT02104947)
Ongoing (NCT02329327) No
Pro-coagulation signals No Decrease of tissue factor pathway
inhibitor activity
No
The clinical development program for Ciraparantag is currently at the Phase II stage, it is not possible to comment on the dose that will be studied in the Phase III trial and which is
therefore more likely to be approved for clinical use.
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retrospective,33 and prospective clinical trials.34 – 37 In Supplemen-
tary material online, surrogate endpoints for measuring the reversal
of NOAC effects with CFCs are critically appraised. Supplementary
material online, Table S3 gives a detailed description of the available
data for reversal of NOAC effects with CFCs based on normaliza-
tion of coagulation tests, ex vivo thrombus generation (TG) or animal
bleeding models. In summary, the evidence supporting the efficacy
and safety of CFCs in case of severe or life-threatening bleeding is
based on laboratory or animal studies, case reports and a Phase I
trial using punch biopsies38 but not on well-designed clinical trials
so far. The results are contradictory with regard to an overall rever-
sal of NOAC effects by CFCs and the preference of one specific
CFC. Furthermore, they are confusing due to the lack of correlation
between the correction of routine laboratory tests, TG, and bleed-
ing in animal models. In particular, animal data suggest that a high
dose of CFCs (e.g. 50 IU/kg of four-factor PCC) is necessary for a
sufficient reversal effect. Limited animal data suggest that CFCs
may ameliorate the effect of NOACs in case of ICH. An important
drawback of the use of PCCs and rFVIIa may be an increased risk of
thromboembolic complications.29– 32
Pending the availability of robust clinical evidence of a beneficial
effect, if immediate haemostatic support is required due to a life-
threatening situation, the choice of CFCs may be based on its least
pro-thrombotic effect, favouring PCCs over rFVIIa. If a four-factor
PCC is used, a high dose or repeated dose is recommended. Finally,
the choice of a CFC must be individually assessed according to drug
availability and experience of the centre, institutional transfusion
guidelines and available consensus among cardiologists, haemostasis
experts, and emergency physicians. Although pro-haemostatic
agents may also limit the extent of bleeding in patients with ICH,
their effect on mortality and disability is unknown.39
The potential benefit of specific
reversal agents for non-vitamin K
antagonist oral anticoagulants
A number of new reversal agents are under development, including
monoclonal antibodies, decoy receptors, and small molecules with
high affinity for NOACs (Table 2). These agents aim to specifically,
completely, and rapidly reverse the effect of NOACs (Figure 2). An-
other perceived advantage of these reversal agents is the lack of a
pro-thrombotic effect of the agents themselves. However, the
sole interruption of anticoagulation therapy may be associated
with an increased risk of thromboembolic events. Accordingly, in
Phase III trials for AF, an increased thromboembolic risk has been
observed at the end of the study after study treatment has been
stopped.7 Despite the assumed high efficiency of specific reversal
agents, their effectiveness in preventing clinical events needs to be
determined. Specifically, life-threatening situations with impairment
of renal and liver function will constitute a challenge for improve-
ment of survival by specific reversal of NOAC effects.
Idarucizumab, an antibody fragment
targeting dabigatran
Idarucizumab (BI 655075) is a humanized, highly selective, and spe-
cific monoclonal antibody fragment (fab) which binds dabigatran
with high affinity (dissociation constant, KD, 2.1 pM), i.e. 350 times
stronger than for thrombin. It rapidly (,5 min) and completely in-
hibited the anticoagulant activity of dabigatran in ex vivo human clot-
ting tests (half maximal inhibitory concentration [IC50] of 2–5 nM)
as well as in in vivo models, exerting a sustained effect for up to 6 h
after intravenous (i.v.) injection.40 However, idarucizumab has no
direct activity on coagulation or platelet aggregation.40,41 In Phase
I placebo-controlled studies, ecarin clotting time (ECT) and diluted
thrombin time (dTT) were significantly prolonged with dabigatran
and reversed to control levels after i.v. dosing with idarucizumab
(1, 2, 4, and 5 + 2.5 g) in 47 men.42 It was found to be safe and ef-
fective, in that dTT was almost immediately corrected.41,42 For the
1 g dose, there was partial return of dabigatran-induced anticoagu-
lation accompanied by an increase of unbound dabigatran concen-
trations 2–4 h after i.v. infusion.42,43 Additionally, idarucizumab
reversed dabigatran-induced inhibition of wound site fibrin forma-
tion.44 In another 46 male and female volunteers, 2.5–5 g of idaru-
cizumab resulted in immediate, complete, and sustained reversal of
dabigatran-induced anticoagulation. The reversal effect was consist-
ent for elderly and renally impaired subjects [creatinine clearance
(CrCl) 30 to ,90 mL/min).43 Dabigatran anticoagulation could be
re-established 24 h after idarucizumab dosing.
An uncontrolled Phase III study (RE-VERSE AD) will assess for the
reversal of the anticoagulant effects of dabigatran by the i.v. admin-
istration of 5 g of idarucizumab in dabigatran-treated patients, who
have uncontrolled bleeding or require emergency surgery or proce-
dures (NCT0210494).45 Up to 300 dabigatran-treated patients with
uncontrollable overt bleeding in need of reversal as judged by the
attending physician (group A), OR in need of emergency surgery
or procedures within the first 4 h (group B) will be enrolled. Patients
with bleeding manageable conservatively (group A) or requiring sur-
gery where the risk of uncontrolled or unmanageable bleeding is
low (group B) are excluded. The primary endpoint is the maximum
reversal of anticoagulant effect of dabigatran in the first 4 h mea-
sured with a specific coagulation test (dTT or ECT). A first interim
analysis has been performed in 90 patients (A: n ¼ 51, B: n ¼ 39,
median age 76.5 years, median CrCl 58 mL/min). The most com-
mon bleeding events in group A were GI bleeding (n ¼ 20) and
ICH (n ¼ 18). Overall, 22 patients were excluded from further ana-
lysis as they already had normal coagulation tests at baseline. Idaru-
cizumab rapidly and completely reversed the anticoagulant activity
of dabigatran in 88–98% of patients.46 In parallel, the concentration
of unbound dabigatran was reduced to a level at or near the lower
limit of quantification. In few patients, a rebound of the effect of idar-
ucizumab was observed after 12 h (n ¼ 6) and 24 h (n ¼ 16), prob-
ably due to redistribution of extravascular dabigatran into the
intravascular compartment. These results confirm successful rever-
sal of the specific effect of dabigatran in critically ill patients who suf-
fer uncontrollable bleeding or who require emergency surgery
while on dabigatran. With regard to clinical bleeding, haemostasis
was restored after a median of 11.4 h in group A. In group B, normal
intraoperative haemostasis was observed in 92% of patients. How-
ever, this normalization of haemostasis did not prevent 18 deaths.
One thrombotic event was observed within 72 h after administra-
tion of idarucizumab and another four events after 72 h. A con-
trolled design against placebo or CFCs would perhaps have been
better, to assess the impact of the reversal on the clinical course
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of patients. But, given the clinical type of the RE-VERSE AD trial pa-
tients, such a design presents major ethical challenges. The interim
analysis of the RE-VERSE AD trial led to the approval of idarucizu-
mab by the European Medicines Agency and the U.S. Food and Drug
Administration.
Andexanet (PRT064445), a truncated
human recombinant FXa
Andexanet alpha (AnXa; PRT064445), a truncated human recom-
binant FXa, is catalytically inactive and lacks the membrane-binding
domain of native FXa but retains the ability of native FXa to bind
direct FXa inhibitors as well as low-molecular-weight heparin-
activated antithrombin III with high-affinity (mean KD 0.5–1.5 nM
for direct FXa inhibitors).47 It acts as a decoy receptor and com-
petes with native FXa, thereby reversing the anticoagulant effects
of all FXa inhibitors. AnXa dose-dependently reversed the inhibition
of FXa activity by FXa inhibitors and corrected clot formation ex
vivo.47 In animal bleeding models, it reduced blood loss and restored
haemostasis after pretreatment with rivaroxaban as well as indirect
FXa inhibitors (low-molecular-weight heparins and fondaparinux).
The effect of AnXa correlated with the reduction in free FXa inhibi-
tor plasma levels and peak anti-FXa activity. However, AnXa did not
interfere with normal FXa function in haemostasis and did not have
anticoagulant activity. In a Phase I study involving 32 healthy volun-
teers not on anticoagulant therapy, AnXa proved to be safe and well
tolerated.48
A placebo-controlled Phase II trial (NCT01758432) investigated
the reversal effect of AnXa after dosing to steady state with direct
and indirect FXa inhibitors in healthy volunteers. Boluses of AnXa
ranging from 210 to 800 mg were used for reversal of FXa inhibi-
tors.49,50 A dose-dependent reversal of the anticoagulant effect
was observed when measuring anti-FXa activity with a maximum
decrease of .90%.50 A subsequent infusion of 4–8 mg AnXa/min
for 1–2 h preserved the reversal effect. Anti-FXa activity returned
to placebo levels 2 h after the end of AnXa infusion. In parallel, plas-
ma concentrations of unbound FXa inhibitors decreased immediate-
ly after AnXa bolus. Thrombus generation and clotting time were
also dose-dependently reversed by AnXa. No thrombotic or ser-
ious adverse events were observed. However, tissue factor pathway
inhibitor activity also decreased due to its binding to AnXa. These
results suggest that AnXa has the potential to be a universal antidote
for reversal of anticoagulation produced by direct and indirect FXa
inhibitors.
In a next step, AnXa was tested in older healthy volunteers meas-
uring anti-FXa activity. The first ANNEXA-A trial (NCT02207725)
tested the reversal of apixaban 5 mg twice daily given for 4 days to
33 healthy volunteers aged 50–70 years. AnXa 400 mg i.v. bolus
showed a 94% complete reversal rate, effectively and rapidly revers-
ing the anticoagulant effect of apixaban.51 No serious adverse events
or thrombotic events were observed. In the second ANNEXA-A
trial, AnXa will be administered as 400 mg i.v. bolus followed by a
continuous infusion of 4 mg/min for 120 min. In the ANNEXA-R
trial (NCT02220725), the reversal of rivaroxaban will be tested in
older healthy volunteers.52 ANNEXA-E for reversal of edoxaban
is planned.
A Phase III trial will evaluate the safety and ability of AnXa in re-
versing the effect of Xa inhibitors in patients with an acute major
Figure 2 Mechanism of non-vitamin K antagonist oral anticoagulants and their antidotes adapted from Enriquez et al.63 The prothrombinase
complex, consisting of FXa and FIIa, catalyses the conversion of pro-thrombin (II) to thrombin (IIa), leading to fibrin generation and clot formation.
The effect of the thrombin inhibitor dabigatran (dab) may be reversed by idarucizumab, a humanized antibody fragment against dabigatran OR
ciraparantag, a small synthetic molecule competitively binding the non-vitamin K antagonist oral anticoagulants (A). The effect of the FXa inhibitors
(a-Xa) apixaban, edoxaban and rivaroxaban may be reversed by andexanet alpha, a modified inactive recombinant FXa competitively binding
circulating FXa inhibitors OR ciraparantag (B).
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bleeding episode (NCT02329327). Like RE-VERSE AD testing idar-
ucizumab, this will be an uncontrolled, open-label study. The pri-
mary endpoint will be the proportion of patients with excellent
or good haemostasis.
Ciraparantag (PER977), a small-molecule
antagonist
Ciraparantag (PER977) is a synthetic, peptide-like, small molecule
designed for the reversal of oral direct FXa and FIIa inhibitors,
low-molecular-weight heparins, unfractionated heparin, and fonda-
parinux but not VKA. Given the molecular structure of PER977,
immunogenic reactions are unlikely.
In ex vivo studies, PER977 completely reversed the anticoagulant
activity of rivaroxaban and apixaban measured with anti-FXa activity
in human plasma.53 No pro-coagulant effects were observed. In an-
imals treated with high doses of edoxaban, PER977 reduced blood
loss in bleeding models (rat tail transection).54 Similar results were
observed with rivaroxaban, apixaban, and dabigatran.55,56 In parallel,
PER97 restored global coagulation tests to baseline levels within
20 min. Additionally, no pro-coagulant effects were observed.55 In
a liver laceration model, the highest investigated dose of PER977
and AnXa showed a similar reduction of blood loss in rabbits
pretreated with rivaroxaban.57 However, PER977 did not affect
anti-FXa activity in this model.
A Phase I trial (NCT01826266) evaluated the safety, tolerabil-
ity, and plasma and urinary pharmacokinetics of a wide range
of single i.v. doses of PER977 (5–300 mg) administered either
alone or following a single dose of edoxaban.58 PER977
.100 mg reversed edoxaban 60 mg within 10 min and restored
clot formation without rebound signals for 24 h.59 No pro-
coagulant effects were observed. In this first trial, PER977 was
safe and well tolerated.
An ongoing clinical trial (NCT02207257) evaluates the safety,
tolerability, and effect on whole blood clotting time of escalating
intravenous doses of PER977 (25, 50, 100, 300, and 600 mg) admi-
nistered after 60 mg edoxaban as a ‘rescue’ medication in healthy
volunteers and repeated for a second day to investigate any effects
of PER977 on the re-anticoagulation with edoxaban and second re-
versal with PER977 (NCT02207257). Phase III clinical trial results
need to be awaited to assess the full clinical therapeutic potential
of this promising new NOAC antidote.
Areas of future research
While traditional controlled Phase III trials may not be feasible in this
area of research in future, an accumulating body of evidence from
observational real-world studies will be even more important.60
Areas of uncertainty to be addressed in future studies include
(i) the risk of thromboembolic events in patients with immediate
reversal of anticoagulation (with reversal agents without a pro-
thrombotic effect per se); (ii) the net clinical benefit of specific anti-
dotes, particularly in patients with severe but not life-threatening
bleeding or urgent surgery; (iii) the effect of specific reversal agents
on clinical events with specific focus on ICH; and (iv) the effect of
specific reversal agents in patients with spontaneous and provoked
bleeding.
Conclusions
While available clinical data for specific antidotes of NOACs are lim-
ited, it is very likely that these agents will successfully reverse the ef-
fect of NOACs as measured by specific coagulation tests. Another
perceived advantage is the lack of a pro-thrombotic effect of the
agent itself. However, uncontrolled studies will not give a definite
answer to the question whether the clinical outcome will be im-
proved. In the absence of specific antidotes, CFCs and/or haemodi-
alysis for dabigatran may be a valuable alternative and may be used in
addition to specific reversal agents in case of liver or renal failure.
Before considering the use of a reversal agent for NOACs, a com-
prehensive pharmacological and clinical assessment of the usually
complex situation of a critically ill patient is essential (Table 3). Fur-
thermore, a set of general measures should precede the use of a re-
versal agent, as depicted in Figure 1. While the availability of specific
reversal agents will increase the confidence in the benefit of
NOACs in clinical practice, an overuse of specific reversal agents
(beyond the tested indications) is of unclear advantage for patients.
Prevention of bleeding in patients with NOACs by managing the
bleeding risk of the patient and by respecting dose-reduction cri-
teria61 and contraindications remains essential. Even in patients
who have survived life-threatening bleeding, restarting anticoagula-
tion therapy is associated with reduced risks of thromboembolic
events and mortality without increasing the risk of bleeding.62
Thus, a timely restart of anticoagulant therapy (or alternative thera-
peutic strategies such as left atrial appendage occlusion) should be
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 3 Initial assessment of patients with a major bleeding event or requiring emergency surgery
Pharmacological considerations Clinical considerations
– Identification of specific NOAC and dose
– Time elapsed since last dose
– Renal function e.g. with estimated glomerular filtration rate determining
half-life of NOAC
– Liver function and signs of coagulopathy
– Specific anticoagulation test or if not available screening test
(aPTT, pro-thrombin time, and anti-FXa activity)
– Signs of haemodynamic instability
– Identification of bleeding source according to bleeding profile of
patient and OAC
– Reason for emergency surgery
– Assessment of thromboembolic (CHA2DS2-VASc) and bleeding risk
(HAS-BLED)
NOAC, non-vitamin K antagonist oral anticoagulant; aPTT, activated partial thromboplastin time; OAC, oral anticoagulant.
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considered depending on the cause and the reversibility of the index
bleeding event.
Consensus statements
– Global coagulation tests are not appropriate for measuring suc-
cessful reversal of NOAC effects (ex vivo studies). Specific coagu-
lation tests for the respective NOAC should be used.
– CFCs should be used in case of life-threatening bleeding or emer-
gency surgery in NOAC-treated patients when a specific reversal
agent is not available or there are signs of systemic coagulopathy.
There is no consistent superior effect of a specific CFC (ex vivo
studies and animal studies). Pro-thrombin complex concentrates
should be preferred over rFVIIa based on the inherent pro-
thrombotic risk.
– Idarucizumab, the first reversal agent tested in critically ill pa-
tients, is effective in reversing the effect of dabigatran measured
by specific coagulation tests (uncontrolled clinical study) and has
been approved by the European Medicines Agency and the U.S.
Food and Drug Administration. Andexanet a targets the effect of
direct and indirect FXa inhibitors and has been successfully
tested in healthy volunteers so far. Ciraparantag (PER977) is de-
signed to antagonize direct and indirect FXa inhibitors as well as
dabigatran. In a Phase I study, PER977 was safe and well tolerated.
Once approved by regulatory authorities, the use of specific anti-
dotes for NOACs should be restricted to life-threatening bleed-
ing or emergency surgery. Discontinuation of NOACs may be
sufficient due to their rather short half-life for other situations re-
quiring improved haemostasis. The effect of reversal agents on
the clinical outcome in critically ill patients can only be assessed
in controlled trials.
– While specific antidotes for NOACs may not have an inherent
pro-thrombotic effect, the sudden termination of anticoagulation
in patients with a significant pro-thrombotic risk may cause
thromboembolic events (Phase III study). The time point of
restarting anticoagulation may therefore be crucial for the net
clinical benefit.
Authors’ contributions
A.N., L.K., J.T., J.M., G.Y.H.L., S.W., and F.W.A.V.: drafted the manu-
script. A.N., J.T., J.M., L.K., S.W., S.E.H., C.T.-P., K.K., B.S.L., H.D.,
J.C.K., D.A., R.F.S., G.Y.H.L., F.W.A.V., and S.A.: made critical revision
of the manuscript for key intellectual content.
Supplementary material
Supplementary Material is available at European Heart Journal online.
Conflict of interest: A.N. reports grants, personal fees, and
non-financial support from Bo¨hringer-Ingelheim, personal fees
from Pfizer, personal fees from Bristol-Myers-Squibb, personal
fees, and non-financial support from Daiichi-Sankyo, personal fees
from Bayer, outside the submitted work. Juan Tamargo reports
grants from Astrazeneca, outside the submitted work. Joa˜o Morais
reports personal fees from Astrazeneca, personal fees from bayel
healthcare, personal fees from BMS/Pfizer, personal fees from
Lilly/Daiichi-Sankyo, personal fees from Boehringer Ingheleim,
personal fees from Merck Sharp and Dhome, outside the submitted
work. Lorenz Koller has nothing to disclose. Sven Wassmann re-
ports personal fees from Bristol–Myers-Squibb, personal fees
from Pfizer, personal fees from Boehringer-Ingelheim, personal
fees from Bayer Healthcare, personal fees from Merck Sharp
Dohme, personal fees from AstraZeneca, personal fees from No-
vartis, outside the submitted work. Steen Elkjær Husted reports
grants from Boehringer-Ingelheim, personal fees from Boehringer-
Ingelheim, personal fees from Bayer, personal fees from BMS, per-
sonal fees from Pfizer, personal fees from AstraZeneca, during the
conduct of the study. Christian Torp-Pedersen reports grants and
personal fees from Bayer, outside the submitted work. Keld Kjeld-
sen has nothing to disclose. Basil S. Lewis reports grants and person-
al fees from Pfizer, grants, and personal fees from BMS, grants from
AstraZeneca, personal fees from Merck, outside the submitted
work. Heinz Drexel reports personal fees from Bayer, personal
fees from Bo¨hringer-Ingelheim, personal fees from Pfizer, during
the conduct of the study; personal fees from Bayer, personal fees
from Bo¨hringer-Ingelheim, personal fees from Pfizer, outside the
submitted work. Juan Carlos Kaski reports personal fees from Sano-
fi, personal fees from Servier UK, personal fees from Menarini UK,
outside the submitted work. Dan Atar reports personal fees from
BMS/Pfizer, personal fees from Boehringer-Ingelheim, personal
fees from Bayer Healthcare, outside the submitted work. Robert
F. Storey reports grants, personal fees, and other from AstraZeneca,
personal fees from Aspen, personal fees from PlaqueTec, personal
fees from The Medicines Company, personal fees from Thermo-
Fisher Scientific, grants and personal fees from Merck, personal
fees from Correvio, personal fees from Roche, personal fees from
Regeneron, personal fees from Sanofi-Aventis, personal fees and
non-financial support from Accumetrics, personal fees from Daiichi-
Sankyo/Eli Lilly, outside the submitted work. In addition, R.F.S. has a
patent related to PEGASUS TIMI 54 study results (no financial inter-
est) pending. Gregory Y. H. Lip has served as a consultant for Bayer,
Astellas, Merck, AstraZeneca, Sanofi, BMS/Pfizer, Biotronik, Portola,
and Boehringer-Ingelheim and has been on the speakers bureau for
Bayer, BMS/Pfizer, Boehringer-Ingelheim, and Sanofi-Aventis, out-
side the submitted work. Freek W.A. Verheugt reports personal
fees from Boehringer-Ingelheim, personal fees from Bristol-Myers-
Squibb, personal fees from Daiichi-Sankyo, personal fees from Bayer
Healthcare, during the conduct of the study. Stefan Agewall has
nothing to disclose.
References
1. Gallego P, Roldan V, Marin F, Romera M, Valdes M, Vicente V, Lip GY. Cessation
of oral anticoagulation in relation to mortality and the risk of thrombotic events
in patients with atrial fibrillation. Thromb Haemost 2013;110:1189–1198.
2. De Caterina R, Husted S, Wallentin L, Agnelli G, Bachmann F, Baigent C,
Jespersen J, Kristensen SD, Montalescot G, Siegbahn A, Verheugt FW, Weitz J. An-
ticoagulants in heart disease: current status and perspectives. Eur Heart J 2007;28:
880–913.
3. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J,
Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R,
Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L. Dabigatran versus war-
farin in patients with atrial fibrillation. N Engl J Med 2009;361:1139–1151.
4. Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L. Newly identified events
in the RE-LY trial. N Engl J Med 2010;363:1875–1876.
5. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M,
Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD,
Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S,
Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS,
Reversal strategies for NOACs Page 7 of 9
 by guest on D
ecem
ber 28, 2015
http://eurheartj.oxfordjournals.org/
D
ow
nloaded from
 
Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L. Apix-
aban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:
981–992.
6. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL,
Waldo AL, Ezekowitz MD, Weitz JI, Spinar J, Ruzyllo W, Ruda M, Koretsune Y,
Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM. Edox-
aban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;369:
2093–2104.
7. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G,
Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF,
Berkowitz SD, Fox KA, Califf RM. Rivaroxaban versus warfarin in nonvalvular atrial
fibrillation. N Engl J Med 2011;365:883–891.
8. Fang MC, Go AS, Chang Y, Hylek EM, Henault LE, Jensvold NG, Singer DE. Death
and disability from warfarin-associated intracranial and extracranial hemorrhages.
Am J Med 2007;120:700–705.
9. Gomez-Outes A, Terleira-Fernandez AI, Calvo-Rojas G, Suarez-Gea ML,
Vargas-Castrillon E. Dabigatran, rivaroxaban, or apixaban versus warfarin in pa-
tients with nonvalvular atrial fibrillation: a systematic review and meta-analysis of
subgroups. Thrombosis 2013;2013:640723.
10. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD,
Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM. Compari-
son of the efficacy and safety of new oral anticoagulants with warfarin in patients
with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014;383:
955–962.
11. Hagii J, Tomita H, Metoki N, Saito S, Shiroto H, Hitomi H, Kamada T, Seino S,
Takahashi K, Baba Y, Sasaki S, Uchizawa T, Iwata M, Matsumoto S, Osanai T,
Yasujima M, Okumura K. Characteristics of intracerebral hemorrhage during rivar-
oxaban treatment: comparison with those during warfarin. Stroke 2014;45:
2805–2807.
12. Larsen TB, Rasmussen LH, Skjoth F, Due KM, Callreus T, Rosenzweig M, Lip GY.
Efficacy and safety of dabigatran etexilate and warfarin in ‘real-world’ patients
with atrial fibrillation: a prospective nationwide cohort study. J Am Coll Cardiol
2013;61:2264–2273.
13. Graham DJ, Reichman ME, Wernecke M, Zhang R, Southworth MR, Levenson M,
Sheu TC, Mott K, Goulding MR, Houstoun M, MaCurdy TE, Worrall C, Kelman JA.
Cardiovascular, bleeding, and mortality risks in elderly medicare patients treated
with dabigatran or warfarin for non-valvular atrial fibrillation. Circulation 2015;
131:157–164.
14. Dogliotti A, Giugliano RP. A novel approach indirectly comparing benefit–risk bal-
ance across anti-thrombotic therapies in patients with atrial fibrillation. Eur Heart J
Cardiovasc Pharmacother 2015;1:15–28.
15. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-
friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients
with atrial fibrillation: the Euro Heart Survey. Chest 2010;138:1093–1100.
16. Roldan V, Marin F, Fernandez H, Manzano-Fernandez S, Gallego P, Valdes M,
Vicente V, Lip GY. Predictive value of the HAS-BLED and ATRIA bleeding scores
for the risk of serious bleeding in a ‘real-world’ population with atrial fibrillation
receiving anticoagulant therapy. Chest 2013;143:179–184.
17. Lip GY, Frison L, Halperin JL, Lane DA. Comparative validation of a novel risk score
for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the
HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding His-
tory or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score.
J Am Coll Cardiol 2011;57:173–180.
18. Lopes RD, Al-Khatib SM, Wallentin L, Yang H, Ansell J, Bahit MC, De Caterina R,
Dorian P, Easton JD, Erol C, Ezekowitz JA, Gersh BJ, Granger CB, Hohnloser SH,
Horowitz J, Hylek EM, McMurray JJ, Mohan P, Vinereanu D, Alexander JH. Efficacy
and safety of apixaban compared with warfarin according to patient risk of stroke
and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled
trial. Lancet 2012;380:1749–1758.
19. Chan P-H, Li W-H, Hai J-J, Chan K-H, Tse H-F, Cheung BM-Y, Chan EW,
Wong ICK, Leung W-K, Hung IF-N, Lip GYH, Siu C-W. Gastrointestinal haemor-
rhage in atrial fibrillation patients: impact of quality of anticoagulation control.
Eur Heart J Cardiovasc Pharmacother 2015;1:265–272.
20. Majeed A, Hwang HG, Connolly SJ, Eikelboom JW, Ezekowitz MD, Wallentin L,
Brueckmann M, Fraessdorf M, Yusuf S, Schulman S. Management and outcomes
of major bleeding during treatment with dabigatran or warfarin. Circulation 2013;
128:2325–2332.
21. Hylek EM, Held C, Alexander JH, Lopes RD, De Caterina R, Wojdyla DM, Huber K,
Jansky P, Steg PG, Hanna M, Thomas L, Wallentin L, Granger CB. Major bleeding in
patients with atrial fibrillation receiving apixaban or warfarin: the ARISTOTLE Trial
(Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial
Fibrillation): predictors, Characteristics, and Clinical Outcomes. J Am Coll Cardiol
2014;63:2141–2147.
22. Heidbuchel H, Verhamme P, Alings M, Antz M, Diener HC, Hacke W, Oldgren J,
Sinnaeve P, Camm AJ, Kirchhof P. Updated European Heart Rhythm Association
Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients
with non-valvular atrial fibrillation. Europace 2015;17:1467–1507.
23. Siegal DM, Crowther MA. Acute management of bleeding in patients on novel oral
anticoagulants. Eur Heart J 2013;34:489–498b.
24. Kaatz S, Kouides PA, Garcia DA, Spyropolous AC, Crowther M, Douketis JD,
Chan AK, James A, Moll S, Ortel TL, Van Cott EM, Ansell J. Guidance on the emer-
gent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol 2012;
87(Suppl. 1):S141–S145.
25. Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, Sinnaeve P,
Camm AJ, Kirchhof P. EHRA practical guide on the use of new oral anticoagulants
in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J 2013;
34:2094–2106.
26. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G,
Kirchhof P. 2012 focused update of the ESC Guidelines for the management of at-
rial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial
fibrillation. Developed with the special contribution of the European Heart Rhythm
Association. Eur Heart J 2012;33:2719–2747.
27. Levi M, Levy JH, Andersen HF, Truloff D. Safety of recombinant activated factor VII
in randomized clinical trials. N Engl J Med 2010;363:1791–1800.
28. Roberts HR, Monroe DM, White GC. The use of recombinant factor VIIa in the
treatment of bleeding disorders. Blood 2004;104:3858–3864.
29. Dentali F, Marchesi C, Pierfranceschi MG, Crowther M, Garcia D, Hylek E,
Witt DM, Clark NP, Squizzato A, Imberti D, Ageno W. Safety of prothrombin
complex concentrates for rapid anticoagulation reversal of vitamin K antagonists.
A meta-analysis. Thromb Haemost 2011;106:429–438.
30. Majeed A, Eelde A, Agren A, Schulman S, Holmstrom M. Thromboembolic safety
and efficacy of prothrombin complex concentrates in the emergency reversal of
warfarin coagulopathy. Thromb Res 2012;129:146–151.
31. Hsia CC, Chin-Yee IH, McAlister VC. Use of recombinant activated factor VII
in patients without hemophilia: a meta-analysis of randomized control trials.
Ann Surg 2008;248:61–68.
32. Yank V, Tuohy CV, Logan AC, Bravata DM, Staudenmayer K, Eisenhut R,
Sundaram V, McMahon D, Olkin I, McDonald KM, Owens DK, Stafford RS. System-
atic review: benefits and harms of in-hospital use of recombinant factor VIIa for
off-label indications. Ann Intern Med 2011;154:529–540.
33. Song MM, Warne CP, Crowther MA. Prothrombin complex concentrate (PCC,
Octaplex) in patients requiring immediate reversal of vitamin K antagonist anticoa-
gulation. Thromb Res 2012;129:526–529.
34. Lubetsky A, Hoffman R, Zimlichman R, Eldor A, Zvi J, Kostenko V, Brenner B.
Efficacy and safety of a prothrombin complex concentrate (Octaplex) for rapid
reversal of oral anticoagulation. Thromb Res 2004;113:371–378.
35. Pabinger I, Brenner B, Kalina U, Knaub S, Nagy A, Ostermann H. Prothrombin
complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a
prospective multinational clinical trial. J Thromb Haemost 2008;6:622–631.
36. Preston FE, Laidlaw ST, Sampson B, Kitchen S. Rapid reversal of oral anticoagulation
with warfarin by a prothrombin complex concentrate (Beriplex): efficacy and safety
in 42 patients. Br J Haematol 2002;116:619–624.
37. Sarode R, Milling TJ Jr, Refaai MA, Mangione A, Schneider A, Durn BL, Goldstein JN.
Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on
vitamin K antagonists presenting with major bleeding: a randomized, plasma-
controlled, phase IIIb study. Circulation 2013;128:1234–1243.
38. Zahir H, Brown KS, Vandell AG, Desai M, Maa JF, Dishy V, Lomeli B, Feussner A,
Feng W, He L, Grosso MA, Lanz HJ, Antman EM. Edoxaban effects on bleeding fol-
lowing punch biopsy and reversal by a 4-factor prothrombin complex concentrate.
Circulation 2015;131:82–90.
39. Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN, Skolnick BE,
Steiner T. Efficacy and safety of recombinant activated factor VII for acute intracer-
ebral hemorrhage. N Engl J Med 2008;358:2127–2137.
40. Schiele F, van Ryn J, Canada K, Newsome C, Sepulveda E, Park J, Nar H,
Litzenburger T. A specific antidote for dabigatran: functional and structural charac-
terization. Blood 2013;121:3554–3562.
41. Glund S, Moschetti V, Norris S, Stangier J, Schmohl M, van Ryn J, Lang B, Ramael S,
Reilly P. A randomised study in healthy volunteers to investigate the safety, toler-
ability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran.
Thromb Haemost 2015;113:943–951.
42. Glund S, Stangier J, Schmohl M, Gansser D, Norris S, van Ryn J, Lang B, Ramael S,
Moschetti V, Gruenenfelder F, Reilly P, Kreuzer J. Safety, tolerability, and efficacy of
idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy
male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial.
Lancet 2015;386:680–690.
43. Glund S, Stangier J, Schmohl M, Moschetti V, Haazen W, De Smet M, Gansser D,
Norris S, Lang B, Reilly P. ABSTRACT: idarucizumab, a specific antidote for dabiga-
tran: immediate, complete and sustained reversal of dabigatran induced anticoagu-
lation in elderly and renally impaired subjects. Blood 2014;124.
A. Niessner et al.Page 8 of 9
 by guest on D
ecem
ber 28, 2015
http://eurheartj.oxfordjournals.org/
D
ow
nloaded from
 
44. van Ryn J, Schmoll M, Pillu H, Gheyle L, Brys J, Moschetti V, Glund S, Reilly P,
Stangier J. ABSTRACT: effect of dabigatran on the ability to generate fibrin at a
wound site and its reversal by idarucizumab, the antidote to dabigatran, in healthy
volunteers: an exploratory marker of blood loss. Circulation 2014;130:A18403.
45. Pollack CV Jr, Reilly PA, Bernstein R, Dubiel R, Eikelboom J, Glund S, Huisman MV,
Hylek E, Kam CW, Kamphuisen PW, Kreuzer J, Levy JH, Sellke F, Stangier J,
Steiner T, Wang B, Weitz JI. Design and rationale for RE-VERSE AD: a phase 3 study
of idarucizumab, a specific reversal agent for dabigatran. Thromb Haemost 2015;
114:198–205.
46. Pollack CV, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, Dubiel R,
Huisman MV, Hylek EM, Kamphuisen PW, Kreuzer J, Levy JH, Sellke FW, Stangier J,
Steiner T, Wang B, Kam C-W, Weitz JI. Idarucizumab for dabigatran reversal. NEngl
J Med 2015;373:511–520.
47. Lu G, DeGuzman FR, Hollenbach SJ, Karbarz MJ, Abe K, Lee G, Luan P,
Hutchaleelaha A, Inagaki M, Conley PB, Phillips DR, Sinha U. A specific antidote
for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor
Xa. Nat Med 2013;19:446–451.
48. Dolgin E. Antidotes edge closer to reversing effects of new blood thinners. NatMed
2013;19:251.
49. Crowther M, Levy GG, Lu GM, Leeds J, Lin J, Pratikhya P, Conley PB, Connolly S,
Curnutte JT. ABSTRACT: a phase 2 randomized, double-blind, placebo-controlled
trial demonstrating reversal of edoxaban-induced anticoagulation in healthy sub-
jects by andexanet alfa (PRT064445), a universal antidote for factor Xa (fXa) inhi-
bitors. Blood 2014;124.
50. Crowther M, Lu G, Conley P, Hollenbach S, Castillo J, Lawrence J, Barron L, Levy G,
Connolly S, Curnutte J. ABSTRACT: sustained reversal of apixaban anticoagulation
with andexanet alfa using a bolus plus infusion regimen in a phase 2 placebo con-
trolled trial. Eur Heart J 2014;35:137.
51. Crowther M, Levy GG, Lu GM, Leeds J, Barron L, Conley PB, Castillo J, Curnutte JT,
Connolly S. ANNEXA (TM)-A: a Phase 3 randomized, double-blind, placebo-
controlled trial, demonstrating reversal of apixaban-induced anticoagulation in old-
er subjects by andexanet alfa (PRT064445), a universal antidote for factor Xa (fXa)
inhibitors. Circulation 2014;130:2116–2117.
52. Gold AM, Crowther M, Levy G, Lu G, Leeds J, Barron L, Conley P, Castillo J,
Curnutte J, Connolly S. ABSTRACT: ANNEXA(TM)-R: a phase 3 randomized,
double-blind, placebo-controlled trial, demonstrating reversal of rivaroxaban-
induced anticoagulation in older subjects by andexanet alfa (PRT064445), a univer-
sal antidote for factor Xa (FXa) inhibitors. J Am Coll Cardiol 2015;65; doi:10.1016/
S0735-1097(15)60023-7.
53. Bakhru S, Laulicht B, Jiang X, Chen L, Grosso M, Morishima Y, Brown K,
Masumoto H, Costin J, Steiner S. ABSTRACT: a synthetic small molecule antidote
for anticoagulants. Eur Heart J 2013;34:188–189.
54. Laulicht B, Bakhru S, Jiang X, Chen L, Pan D, Grosso M, Morishima Y, Brown K,
Masumoto H, Costin J, Steiner S. ABSTRACT: antidote for new oral anticoagulants:
mechanism of action and binding specificity of PER977. J Thromb Haemost 2013;11:
75–75.
55. Laulicht B, Bakhru S, Lee C, Baker C, Jang X, Mathiowitz E, Costin J, Steiner S.
ABSTRACT: small molecule antidote for anticoagulants. Circulation 2012;126:
A11395.
56. Bakhru S, Laulicht B, Jiang X, Chen LR, Pan D, Grosso M, Morishima Y, Brown K,
Masumoto H, Costin J, Steiner S. ABSTRACT: a synthetic small molecule which
reverses over-dosage and bleeding by the new oral anticoagulants. Circulation
2013;128:A18809.
57. Hollenbach S, Lu G, DeGuzman F, Tan S, Pratikhya P, Pandey A, Conley P,
Curnutte JT. ABSTRACT: andexanet-alfa and PER977 (Arapazine) correct blood
loss in a rabbit liver laceration model – only andexanet reverses markers of FXa-
mediated anticoagulation. Circulation 2014;130:A14657.
58. Ansell JE, Laulicht B, Bakhru S, Steiner S, Noveck R, Brown K, Grosso M,
Morishima Y, Dishy V, Mercuri M. ABSTRACT: aripazine reverses unfractionated
and low molecular weight heparins, fondaparinux and new Xa and IIa oral anticoa-
gulants: report of Phase I/II clinical trial with edoxaban. Eur Heart J 2014;35:
854–855.
59. Ansell JE, Bakhru SH, Laulicht BE, Steiner SS, Grosso M, Brown K, Dishy V,
Noveck RJ, Costin JC. Use of PER977 to reverse the anticoagulant effect of edox-
aban. N Engl J Med 2014;371:2141–2142.
60. Sarich TC, Seltzer JH, Berkowitz SD, Costin J, Curnutte JT, Gibson CM, Hoffman M,
Kaminskas E, Krucoff MW, Levy JH, Mintz PD, Reilly PA, Sager PT, Singer DE,
Stockbridge N, Weitz JI, Kowey PR. Novel oral anticoagulants and reversal agents:
considerations for clinical development. Am Heart J 2015;169:751–757.
61. Lip GY, Clemens A, Noack H, Ferreira J, Connolly SJ, Yusuf S. Patient outcomes
using the European label for dabigatran. A post-hoc analysis from the RE-LY data-
base. Thromb Haemost 2014;111:933–942.
62. Nielsen PB, Larsen TB, Skjoth F, Gorst-Rasmussen A, Rasmussen LH, Lip GY. Re-
starting anticoagulant treatment after intracranial hemorrhage in patients with atrial
fibrillation and the impact on recurrent stroke, mortality, and bleeding: a Nation-
wide Cohort Study. Circulation 2015;132:517–525.
63. Enriquez A, Lip GY, Baranchuk A. Anticoagulation reversal in the era of the non-
vitamin K oral anticoagulants. Europace 2015; doi: 10.1093/europace/euv030.
Reversal strategies for NOACs Page 9 of 9
 by guest on D
ecem
ber 28, 2015
http://eurheartj.oxfordjournals.org/
D
ow
nloaded from
 
